English हिन्दी
Connect with us

Latest world news

US sells $ 133 million anti-ballistic missiles to Japan

Published

on

US sells $ 133 million anti-ballistic missiles to Japan

Amidst positive developments of dialogue resumption between the two Koreas, The US administration has approved a $133.3 million sale of anti-ballistic missiles to Japan to defend itself from a threat from North Korea.

According to State Department officials, quoted by Fox news, it has notified the Congress on Tuesday asking it to approve the sale of the four missiles for the SM-3 Block IIA interceptor. They say that the proposal “also included four Mk 29 missile canisters, and other technical, engineering and logistics support services.”

During his November visit to Japan, Donald Trump said that Japan would shoot North Korean missiles “out of the sky” if it bought the U.S. weaponry needed for doing for doing so and suggested Tokyo take a stance it has avoided until now.

Trump, went ahead after the summit with Japanese PM Shinzo Abe, saying the “era of strategic patience” with North Korea was over and added that the two countries were working to counter the “dangerous aggressions”.

The fox news quotes the official saying that the sale of the missiles follows through “on President Trump’s commitment to provide additional defensive capabilities to treaty allies threatened by the DPRK’s provocative behavior.”

The proposed sale of anti-Ballistic missiles, if concluded, would contribute to the US “foreign policy and national security interests. It will bolster the security of a major treaty ally that has been, and continues to be, a force for political stability and economic progress in the Asia-Pacific region. It will also improve (Japan Maritime Self-Defense Force’s) interoperability with US missile defense systems, and increase the protection for US installations in the region.”
The missiles, made by Raytheon Co and BAE Systems, can be launched from destroyers at sea or from a land-based system.

Within one month after Trump’s Tokyo sojourn, Japan formally decided to expand its ballistic missile system using US-made ground-based Aegis radar stations and interceptors in December.

Reuters reported in December that the cost of building two Aegis Ashore batteries without the missiles would be at least $2 billion and it was not likely to be operational until 2023 at the earliest.

According to a Pentagon statement issued on Monday, US Secretary of Defense James Mattis and Japanese Minister of Defense Itsunori Onodera “condemned North Korea’s reckless and unlawful behavior,” while talking on phone.

During his maiden foreign trip after occupying White House to Saudi Arabia in May last year, US President Donald Trump had concluded a $110 billion arms deal.

Latest world news

Trump says Iran getting more serious in talks, no decision yet on major strikes

Donald Trump says Iran is becoming more serious in negotiations with the US but insists no decision has been taken on launching major military strikes against Tehran.

Published

on

Donald Trump

US President Donald Trump has said he has not yet decided whether to authorise major military strikes against Iran, stating that Tehran has become “more serious” in its negotiations with Washington even as tensions between the two countries remain high.

Speaking to reporters in the Oval Office on Friday, Trump said discussions with Iran were continuing and suggested diplomatic efforts were showing signs of progress.

“We’re talking to them right now. I think they’re getting more and more serious as the days go by,” Trump said, adding that no final decision had been taken on launching military action.

Trump says diplomacy remains an option

Trump said the United States remained prepared for military action if required but indicated that ongoing talks could still lead to an agreement.

“We’re locked and loaded and ready to go. But we’re talking to them, so I think while we’re talking, we’ll see what comes of it. I believe they’re very serious. They should be,” he said.

The US President also warned that Iran would face a “much higher level” of strikes if negotiations failed, while reiterating that preventing Tehran from developing a nuclear weapon remained his key red line.

The United States has said its military operations are aimed at preventing Iran from closing the strategically important Strait of Hormuz. Iran, meanwhile, has carried out retaliatory strikes on US bases, with four American service members reported killed.

Reports claim Trump discussed large-scale military operation

Trump’s remarks came after media reports suggested he met senior advisers to discuss the possibility of a large-scale military operation against Iran. Another report said he was considering a “massive attack”, although Trump did not confirm those reports during his interaction with journalists.

He also acknowledged that the prolonged conflict, which he had earlier expected to last only a few weeks, was approaching its fifth month and had become a political challenge ahead of the US midterm elections scheduled for November.

Trump issues warning over support for Iran

Trump also addressed reports claiming that Russia and China were providing intelligence or military support to Iran. He said both Chinese President Xi Jinping and Russian President Vladimir Putin had assured him they would not arm Tehran.

“I think they wouldn’t want to have me disappointed,” Trump said.

In a separate post on his Truth Social platform, Trump warned Moscow and Beijing against supplying weapons to Iran, saying such a move would not be in their interests.

He further stated that Xi had assured him during their meeting in Beijing in May that China would not provide weapons to Iran, while Putin had conveyed a similar position despite the ongoing war in Ukraine.

Continue Reading

India News

For second time, US strikes ship with Indian crew near Strait of Hormuz

Published

on

By

Strait of Hormuz

The United States Central Command (CENTCOM) has said that an oil tanker carrying Indian crew was drifting with its engine switched off near the Strait of Hormuz before it was struck by US forces.

A CENTCOM spokesperson said the vessel had stopped due to engine failure and was drifting after its crew repeatedly sought additional time to carry out repairs. US officials said the tanker was struck only after it failed to comply with directives issued by US forces enforcing a blockade on vessels allegedly transporting Iranian oil. The military said the strike was aimed at disabling the ship by targeting its engine room rather than sinking it.

The incident involved a tanker carrying Indian seafarers near the Gulf of Oman, close to the Strait of Hormuz, one of the world’s busiest maritime trade routes. The strike triggered a fire onboard, prompting rescue efforts by Omani authorities and maritime agencies. Indian authorities closely monitored the situation and coordinated with local officials regarding the welfare of the crew members.

The incident has drawn concern in India, with the government emphasising the safety of Indian nationals working aboard commercial vessels in the conflict-hit region. The Ministry of External Affairs has remained in touch with the authorities concerned as tensions between the United States and Iran continue to pose risks to international shipping.

In June, three Indian sailors were killed in a US strike on another oil tanker. The Strait of Hormuz handles a significant share of the word’s oil trade, and the latest incident has renewed concerns over the security of merchant vessels operating in the region. Maritime experts have warned that escalating hostilities could further disrupt commercial shipping and endanger civilian crews navigating one of the world’s most strategically important waterways.

Continue Reading

Latest world news

Trump announces phased tariff of up to 200% on generic drug imports, India may face impact

US President Donald Trump has announced a phased tariff plan on imported generic medicines, raising duties to 200% after three years, a move that could affect India’s pharmaceutical exports.

Published

on

Donald Trump

The United States has announced a phased tariff plan for imported generic medicines that could have implications for pharmaceutical exporters, including India. US President Donald Trump said the policy is intended to encourage companies to shift generic drug manufacturing to the United States by imposing steep tariffs after a two-year transition period.

The announcement is particularly important for India, one of the world’s largest suppliers of affordable generic medicines and a major exporter to the US market.

Trump outlines phased tariff plan

In a post on his Truth Social platform, President Trump said the new policy will take effect from August 1, 2026. Under the plan, imported generic medicines will continue to attract zero tariffs for the first two years.

Beginning in the third year, the tariff will increase to 100%, before rising further to 200% thereafter.

Trump said the measure is designed to encourage pharmaceutical companies to establish manufacturing facilities in the United States instead of relying on imports.

He added that companies choosing not to invest in US-based production during the transition period would face the higher tariff rates. According to Trump, the existing policy governing patented, branded and innovative medicines will remain unchanged.

Why India could be affected

India is widely regarded as the “pharmacy of the world” because of its large-scale production and export of generic medicines.

Indian generic drugs account for nearly 40% of the US generic medicine market by volume. According to a Global Trade Research Initiative (GTRI) report, India exported pharmaceutical products worth USD 9.7 billion to the United States during the 2024-25 financial year, representing around 38% of the country’s total pharmaceutical exports of USD 25.8 billion.

However, the immediate impact of the newly announced tariff policy on Indian pharmaceutical companies remains uncertain.

Existing trade agreement and industry concerns

India and the United States struck a trade pact in February that states India would receive negotiated outcomes regarding generic pharmaceuticals and pharmaceutical ingredients.

Despite that provision, previous tariff threats by Trump had already raised concerns within the pharmaceutical industry over the future of affordable medicine exports from India.

Indian pharmaceutical companies supply a wide range of generic medicines used to treat conditions including hypertension, diabetes, depression, cancer, infectious diseases and mental health disorders.

According to a Financial Post report cited in the source material, around 65% of birth control pill prescriptions in the United States during 2024 were manufactured by two India-based companies — Glenmark Pharmaceuticals Ltd. and Lupin Ltd.

Continue Reading

Trending

© Copyright 2022 APNLIVE.com